Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ith non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry ... market with a focus on the Chinese situation. Major companies included in the propanol ... Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), a ... and marketing biopharmaceutical,products, today announced its unaudited financial ... Second Quarter 2008 Financial Highlights: ... second quarter 2007 to ...
... To protect potential patients from,being unwitting victims in ... Stem Cell Institute LLC (RSCI),( http://www.RepairStemCells.org ) and ... of the industry,s first standards of,excellence for Repair ... RSC, also known as Adult Stem Cells. Among ...
... on Monday, August 18, 2008, ... Beginning at 1:00 PM Eastern Time, LIVINGSTON, N.J., Aug. ... in,advanced injection technologies, today announced that it plans to report,its results ... the morning,of Thursday, August 14, 2008., Milestone Scientific will also ...
Cached Biology Technology:3SBio Inc. Announces Second Quarter 2008 Results 23SBio Inc. Announces Second Quarter 2008 Results 33SBio Inc. Announces Second Quarter 2008 Results 43SBio Inc. Announces Second Quarter 2008 Results 53SBio Inc. Announces Second Quarter 2008 Results 63SBio Inc. Announces Second Quarter 2008 Results 73SBio Inc. Announces Second Quarter 2008 Results 83SBio Inc. Announces Second Quarter 2008 Results 93SBio Inc. Announces Second Quarter 2008 Results 103SBio Inc. Announces Second Quarter 2008 Results 113SBio Inc. Announces Second Quarter 2008 Results 123SBio Inc. Announces Second Quarter 2008 Results 133SBio Inc. Announces Second Quarter 2008 Results 143SBio Inc. Announces Second Quarter 2008 Results 15Repair Stem Cell Institute Announces Industry's First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics 2Milestone to Report Results for 2008 Second Quarter on Thursday, August 14, 2008 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Jan. 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical ... cells and tissues including muscle, bone, fat, red blood ... awarded a $1.5 million grant from the Muscular Dystrophy ... Muscular Dystrophy (DMD), a disabling neuromuscular disease in which ...
... that nations should abandon the concept of carbon emissions ... might lead to genuine reductions in the amount of ... provide a mechanism for reducing climate change. Details of ... Interdisciplinary Environmental Review . Carbon emissions trading ...
... The number of women who die from complications of ... last two decades thanks to improved monitoring and better ... report,s lead researcher, Joy Hawkins, MD, professor of anesthesiology ... Colorado School of Medicine, said the risks have been ...
Cached Biology News:Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2Carbon swap bank to beat climate change 2Carbon swap bank to beat climate change 3Deaths from anesthesia during childbirth plummet 2
... Measurement of light production by luciferase-cDNA ... a valuable technique in the development of ... is used as an indicator for the ... the luciferase enzyme is due to advantages ...
... detection of apoptosis and mitochondrial membrane potential. ... early indication of the initiation of cellular ... a collapse in the electrochemical gradient across ... change in the membrane potential (YD). Loss ...
... kit measures mitochondria intactness and detects ... potential. Features and Benefits: ... staining isolated mitochondria and for assaying ... the reagents required for the detection ...
... is expressed in g per ml and is ... pH 6.8, of a 1 mg per ml ... concentration to agglutinate a 2% suspension of human ... at 25 C. Preparation Note: Affinity ...
Biology Products: